OncoC4, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO100%
Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.0 months). See all sponsors →
Open OncoC4, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PRESERVE-004 NCT05446298 |
P2 | Active, not recruiting | Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary | 58 | 2026-08-30 (+11 mo) |
| PRESERVE-006 NCT05682443 |
P1/2 | Active, not recruiting | Metastatic Castration-resistant Prostate Cancer | 148 | 2026-11-30 (+11 mo) |
| PRESERVE-001 NCT04140526 |
P1/2 | Active, not recruiting | Non Small Cell Lung Cancer; Advanced Solid Tumor | 733 | 2026-12-31 (+59 mo) |
| BiPAVE-001 NCT06635785 |
P1/2 | Recruiting | Advanced Solid Tumor | 387 | 2027-06-30 (+18 mo) |
| PRESERVE-003 NCT05671510 |
P3 | Active, not recruiting | Non Small Cell Lung Cancer | 630 | 2027-08-31 (+14 mo) |
| Gotistobart NCT07659379 |
P3 | Enrolling by invitation | Advanced Solid Tumor | 20 | 2036-07-01 |